Press Releases
Press Releases
| Date | Press Releases | Topic |
|---|---|---|
| Jun 27, 2005 |
Seven Latin American Scientists Named 2005 Pew Latin American Fellows in the Biomedical Sciences The Pew Charitable Trusts and the University of California at San Francisco (UCSF) announced today that seven promising Latin American biomedical scientists have been named 2005 Pew Latin American Fellows in the Biomedical Sciences. |
Biomedical Research |
| Jun 27, 2005 |
Fifteen of America’s Most Promising Biomedical Researchers Chosen as Pew Scholars The Pew Charitable Trusts and the University of California at San Francisco (UCSF) announced today that 15 gifted researchers have been selected as 2005 Pew Scholars in the Biomedical Sciences. |
Biomedical Research |
| Jun 14, 2004 |
Fifteen of America’s Most Gifted Scientists Earn Recognition as 2004 Pew Biomedical Scholars Fifteen of America’s most gifted biomedical scientists have been chosen as 2004 Pew Biomedical Scholars, The Pew Charitable Trusts and the University of California at San Francisco (UCSF) announced today. |
Biomedical Research |
| Feb 1, 2013 |
Pew Commends Strong Transparency Rule for Physician-Industry Relationships Allan Coukell, director of medical programs for The Pew Charitable Trusts, issued the following statement in response to the Centers for Medicare & Medicaid Services' final rule for implementing the Physician Payments Sunshine Act, which will bring transparency to the financial relationships between physicians and drug and medical device companies. |
Conflicts of Interest |
| Dec 14, 2011 |
CMS: Affordable Care Act Sunshine Rule Increases Transparendy in Health Care The Centers for Medicare & Medicaid Services (CMS ) announced today a proposed rule that will increase public awareness of financial relationships between drug and device manufacturers and certain health care providers. |
Conflicts of Interest |
| Mar 22, 2010 |
Pew Prescription Project Statement on the Physician Payments Sunshine Act Allan Coukell, director of the Pew Prescription Project, issued the following statement today, commending Congress for including provisions from the Physician Payments Sunshine Act in health care reform legislation. The provisions would require drug and device companies to publicly report the gifts and payments they make to doctors. |
Conflicts of Interest |
| Jun 16, 2009 |
Over one-fifth of U.S. medical schools improved their conflict-of-interest rules in the past year, yet dozens of others lag behind according to the 2009 American Medical Student Association (AMSA) PharmFree Scorecard, released today. |
Conflicts of Interest |
| Jan 22, 2009 |
“Pharmaceuticals and medical devices clearly play a critical role in patient care. However, aggressive industry marketing of new drugs and devices to doctors through undisclosed gifts, consulting payments, speaking fees, classes, and meals can inappropriately influence medical decisions and create conflicts of interest." |
Conflicts of Interest |
| Jun 18, 2008 |
A majority of Americans (64%) say that it is important to know their physician’s financial ties to pharmaceutical companies and 68% would support legislation requiring pharmaceutical companies to disclose gifts to doctors, according to the results of a new survey released today by the Prescription Project. |
Conflicts of Interest |
| Feb 12, 2007 |
New Campaign Champions Changes in Medical Prescribing to End Conflicts of Interest The Prescription Project called on academic medical centers, professional medical societies and public and private payers to end conflicts of interest resulting from the $12 billion spent annually on pharmaceutical marketing. |
Conflicts of Interest |
| Jul 12, 2011 |
Pew Finds Serious Gaps in Oversight of U.S. Drug Safety Americans’ medicines are increasingly manufactured in developing countries, where oversight is lower than in the U.S., according to a new white paper by the Pew Health Group. The U.S. Food and Drug Administration (FDA) estimates 40 percent of finished drugs and 80 percent of active ingredients and bulk chemicals used in U.S. drugs come from overseas. |
Drug Manufacturing and Distribution, Drug Safety |
| Mar 15, 2011 |
Consumer and Drug Industry Representatives Back New Fees to Cover Inspections Allan Coukell, director of the Medical Safety Division of the Pew Health Group, issued the following statement today, commenting on a March 14-15 conference, "After Heparin: A Roundtable on Ensuring the Safety of the U.S. Drug Supply," in which industry and consumer experts called for changes to address the risk of counterfeit and substandard medicine |
Drug Manufacturing and Distribution, Drug Safety |
| Aug 3, 2010 |
The Pew Prescription Project, joined by major consumer, physician and chemical manufacturer groups, today announced support for a new bill that would give the FDA much-needed authorities to better protect pharmaceutical supply chains. |
Drug Manufacturing and Distribution, Drug Safety |
| Mar 10, 2010 |
Pew Statement On House Hearing Regarding FDA Drug Safety Reforms Allan Coukell, director of the Pew Prescription Project, issued the following statement today, commenting on a hearing at the U.S. House Energy and Commerce Subcommittee on Health, where Food and Drug Administration (FDA) Principal Deputy Commissioner Joshua M. Sharfstein is expected to present testimony regarding the agency’s ability to protect Americans from unsafe drugs made overseas. |
Drug Manufacturing and Distribution, Drug Safety |
| Mar 10, 2010 |
Statement on Congressional Hearing Regarding FDA Drug Safety Reforms Allan Coukell, director of the Pew Prescription Project, issued the following statement today, commenting on a hearing at the U.S. House Energy and Commerce Subcommittee on Health, where Food and Drug Administration (FDA) Principal Deputy Commissioner Joshua M. Sharfstein is expected to present testimony regarding the agency's ability to protect Americans from unsafe drugs made overseas. |
Drug Manufacturing and Distribution, Drug Safety |
| Sep 19, 2012 | Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report shows that many states do not fully analyze the data they collect. | Drug Safety |
| Jul 9, 2012 |
Pew Applauds Enactment of User Fee Legislation, Urges Its Swift Implementation President Barack Obama today signed into law the Food and Drug Administration Safety and Innovation Act, which supports the U.S. Food and Drug Administration’s drug and device reviews and includes other measures to benefit patients. |
Drug Safety, Antibiotic Innovation |
| May 31, 2012 |
Pew Applauds Passage of Bipartisan User Fee Legislation by U.S. House of Representatives The U.S. House of Representatives today passed bipartisan legislation to ensure that the U.S. Food and Drug Administration (FDA) has the funds it needs to approve products that improve health and protect consumers from unnecessary risks. |
Drug Safety, Antibiotic Innovation, Drugs and Devices at the FDA |
| Feb 15, 2012 |
Pew Urges Congress to Pass Medical Device User Fee Act and Improve Marketplace Monitoring We applaud the FDA and the medical device industry for reaching an agreement that will spur the innovation of new therapies for improving health and saving lives. |
Drug Safety, Drugs and Devices at the FDA |
| Jan 13, 2012 |
We commend the FDA and the pharmaceutical industry for working together on agreements that support the agency’s review activities. Under PDUFA, the FDA has reduced the time it takes to approve new drugs. |
Drug Safety, Drugs and Devices at the FDA |
| May 16, 2012 |
FDA Reviews New Drug Applications Faster than European, Canadian Regulators WASHINGTON—The U.S. Food and Drug Administration (FDA) approves new drugs more quickly than its counterparts in Europe and Canada, according to a new paper, “Regulatory Review of Novel Therapeutics Comparing FDA, EMA and Health Canada,” published online on May 16 |
Drugs and Devices at the FDA |
| Oct 26, 2011 |
Food Chemical Regulations Rely Heavily on Industry Self-Policing and Lack Transparency Safety decisions concerning one-third of the more than 10,000 substances that may be added to human food were made by food manufacturers and a trade association without review by the U.S. Food and Drug Administration (FDA), according to an analysis spearheaded by the Pew Health Group. |
Food Additives |
| Jun 14, 2013 |
Pew Commends Rep. Latham on New Food Safety Funding The Pew Charitable Trusts commends Representative Tom Latham (R-IA) for his leadership in securing approximately $27 million for food safety in the House appropriations bill funding the U.S. Food and Drug Administration, or FDA. The new money would help the FDA protect millions of Americans from the dangers of foodborne illnesses and strengthen consumer confidence in the food supply. |
Food Hazards |
| Nov 18, 2011 |
Pew Food Safety Campaign Statement on FDA Funding Legislation Congress’ decision to increase appropriations for the U.S. Food and Drug Administration (FDA) by $39 million provides an important down payment toward the implementation of the FDA Food Safety Modernization Act (FSMA), which was enacted in January. This law, adopted with strong bipartisan support, will strengthen how the federal government oversees the safety of 80 percent of the food supply.
|
Food Hazards |
| May 19, 2011 |
Poll Finds Most Americans Favor Increased Funding for Stronger Food Safety Oversight Among likely voters surveyed across the nation, 66 percent support additional funding for the U.S. Food and Drug Administration (FDA) to carry out new responsibilities related to food safety, according to a Pew-commissioned poll released today by the bipartisan team of Hart Research and American Viewpoint. |
Food Hazards |
